Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (358) 358
Publication (51) 51
Patent (13) 13
Conference Proceeding (12) 12
Book Chapter (7) 7
Book Review (2) 2
Book / eBook (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (231) 231
humans (221) 221
female (205) 205
breast cancer (151) 151
middle aged (150) 150
adult (135) 135
index medicus (131) 131
aged (116) 116
breast neoplasms - drug therapy (114) 114
breast neoplasms - pathology (95) 95
chemotherapy (91) 91
cancer (77) 77
antineoplastic combined chemotherapy protocols - therapeutic use (72) 72
disease-free survival (68) 68
treatment outcome (67) 67
prognosis (65) 65
therapy (63) 63
breast neoplasms - surgery (58) 58
chemotherapy, adjuvant (58) 58
hematology, oncology and palliative medicine (54) 54
breast neoplasms - mortality (53) 53
care and treatment (49) 49
tamoxifen (44) 44
analysis (37) 37
neoplasm staging (37) 37
carcinoma (34) 34
male (34) 34
follow-up studies (33) 33
aged, 80 and over (32) 32
cyclophosphamide (32) 32
surgery (32) 32
antineoplastic combined chemotherapy protocols - administration & dosage (31) 31
survival (31) 31
antineoplastic agents, hormonal - therapeutic use (30) 30
medicine & public health (30) 30
antineoplastic combined chemotherapy protocols - adverse effects (29) 29
breast neoplasms - metabolism (29) 29
clinical trials (29) 29
fluorouracil - administration & dosage (29) 29
receptors, estrogen - metabolism (28) 28
cyclophosphamide - administration & dosage (27) 27
drug administration schedule (27) 27
women (27) 27
metastasis (26) 26
obstetrics & gynecology (26) 26
postmenopausal women (26) 26
research (26) 26
survival analysis (26) 26
endocrine therapy (25) 25
retrospective studies (25) 25
breast neoplasms - therapy (24) 24
estrogen (24) 24
mastectomy (24) 24
tamoxifen - therapeutic use (24) 24
neoadjuvant chemotherapy (23) 23
premenopause (23) 23
receptor, erbb-2 - metabolism (23) 23
tumors (23) 23
adjuvant treatment (22) 22
lymphatic metastasis (22) 22
health aspects (21) 21
randomized-trial (21) 21
survival rate (21) 21
article (20) 20
cancer therapies (20) 20
combined modality therapy (20) 20
methotrexate (20) 20
methotrexate - administration & dosage (20) 20
neoadjuvant therapy (20) 20
antineoplastic agents - therapeutic use (19) 19
immunohistochemistry (19) 19
receptors, progesterone - metabolism (19) 19
trial (19) 19
kaplan-meier estimate (18) 18
oncology, experimental (18) 18
patients (18) 18
menopause (17) 17
primary therapy (17) 17
randomized controlled trials as topic (17) 17
receptors, estrogen - analysis (17) 17
risk factors (17) 17
young adult (17) 17
breast neoplasms - genetics (16) 16
cancer patients (16) 16
highlights (16) 16
letrozole (16) 16
proportional hazards models (16) 16
time factors (16) 16
antineoplastic agents - administration & dosage (15) 15
breast neoplasms - radiotherapy (15) 15
disease progression (15) 15
international expert consensus (15) 15
neoplasm metastasis (15) 15
trastuzumab (15) 15
adjuvant chemotherapy (14) 14
aromatase inhibitors - therapeutic use (14) 14
combination (14) 14
dose-response relationship, drug (14) 14
expression (14) 14
fluorouracil (14) 14
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (370) 370
Italian (7) 7
German (5) 5
French (4) 4
Croatian (1) 1
Danish (1) 1
Hungarian (1) 1
Korean (1) 1
Polish (1) 1
Portuguese (1) 1
Serbian (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Il cinema di Marco Tullio Giordana
: interventi critici
by Lanslots, Inge, editor and Cecchini, Fabiana and Dalla Torre, Elena, editor and Colleoni, Federica, editor
2015, Da lontano, ISBN 8882473694, Volume 6., 317
Giordana, Marco Tullio Criticism and interpretation
Book
Details down arrow
2. Full Text Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
by Cristofanilli, Massimo, Prof and Turner, Nicholas C, MD and Bondarenko, Igor, Prof and Ro, Jungsil, MD and Im, Seock-Ah, MD and Masuda, Norikazu, MD and Colleoni, Marco, MD and DeMichele, Angela, MD and Loi, Sherene, MD and Verma, Sunil, MD and Iwata, Hiroji, MD and Harbeck, Nadia, Prof and Zhang, Ke, PhD and Theall, Kathy Puyana, MD and Jiang, Yuqiu, PhD and Bartlett, Cynthia Huang, MD and Koehler, Maria, MD and Slamon, Dennis, Prof
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 425 - 439
Summary Background In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor palbociclib and fulvestrant was associated with significant... 
Hematology, Oncology and Palliative Medicine | KINASE 4/6 INHIBITOR | SOUTHWEST-ONCOLOGY-GROUP | ONCOLOGY | RESISTANCE | PROGESTERONE-RECEPTOR | MUTATIONS | COMBINATION | AROMATASE INHIBITORS | EXPRESSION | ESTROGEN-RECEPTOR | CHEMOTHERAPY | Piperazines - administration & dosage | Estradiol - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Estradiol - administration & dosage | Treatment Outcome | Breast Neoplasms - drug therapy | Neoplasm Recurrence, Local - pathology | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Neoplasm Metastasis | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Breast Neoplasms - pathology | Adult | Female | Neoplasm Recurrence, Local - genetics | Aged | Mutation | Medical colleges | Care and treatment | Oncology, Experimental | Clinical trials | Breast cancer | Metastasis | Hormones | Research | Antineoplastic agents | Epidemiology | Antimitotic agents | Analysis | Product development | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Clinical overview of metronomic chemotherapy in breast cancer
by Munzone, Elisabetta and Colleoni, Marco
Nature Reviews Clinical Oncology, ISSN 1759-4774, 11/2015, Volume 12, Issue 11, pp. 631 - 644
Over 15 years ago, low-dose metronomic chemotherapy was shown to induce disease control in patients with advanced-stage breast cancer with a lower incidence of... 
PEGYLATED LIPOSOMAL DOXORUBICIN | PHASE-II TRIAL | MAINTENANCE TREATMENT | ONCOLOGY | PRIMARY SYSTEMIC TREATMENT | LOW-DOSE CYCLOPHOSPHAMIDE | REGULATORY T-CELLS | TUMOR ANGIOGENESIS | ORAL VINORELBINE | ELDERLY-PATIENTS | ENDOTHELIAL GROWTH-FACTOR | Female | Antineoplastic Agents - administration & dosage | Administration, Metronomic | Breast Neoplasms - drug therapy | Humans | Randomized Controlled Trials as Topic | Care and treatment | Chemotherapy | Breast cancer | Methods | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Neoadjuvant nab-paclitaxel in breast cancer: trial results and patient care
by Colleoni, Marco
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 265 - 266
Hematology, Oncology and Palliative Medicine | ONCOLOGY | CONSENSUS | THERAPY | Patient Care | Neoadjuvant Therapy | Breast Neoplasms | Humans | Patients | Care and treatment | Breast cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial
by Galimberti, Viviana, Dr and Cole, Bernard F, PhD and Zurrida, Stefano, MD and Viale, Giuseppe, MD and Luini, Alberto, MD and Veronesi, Paolo, MD and Baratella, Paola, MD and Chifu, Camelia, MD and Sargenti, Manuela, MD and Intra, Mattia, MD and Gentilini, Oreste, MD and Mastropasqua, Mauro G, MD and Mazzarol, Giovanni, MD and Massarut, Samuele, MD and Garbay, Jean-Rémi, MD and Zgajnar, Janez, MD and Galatius, Hanne, MD and Recalcati, Angelo, MD and Littlejohn, David, FRACS and Bamert, Monika, MD and Colleoni, Marco, MD and Price, Karen N, BS and Regan, Meredith M, SD and Goldhirsch, Aron, MD and Coates, Alan S, MD and Gelber, Richard D, PhD and Veronesi, Umberto, MD and Int Breast Canc Study Grp Trial 23 and International Breast Cancer Study Group Trial 23-01 investigators
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 4, pp. 297 - 305
Summary Background For patients with breast cancer and metastases in the sentinel nodes, axillary dissection has been standard treatment. However, for patients... 
Hematology, Oncology and Palliative Medicine | INTERNATIONAL EXPERT CONSENSUS | PRIMARY THERAPY | ONCOLOGY | LYMPH-NODES | BIOPSY | METASTASES | INVOLVEMENT | AMERICAN-COLLEGE | HIGHLIGHTS | RECURRENCE | EARLY BREAST-CANCER | Breast Neoplasms - surgery | Lymph Nodes - pathology | Follow-Up Studies | Lymph Nodes - surgery | Humans | Middle Aged | Treatment Outcome | Lymphatic Metastasis | Breast Neoplasms - physiopathology | Disease-Free Survival | Neoplasm Grading | Neoplasm Micrometastasis | Breast Neoplasms - pathology | Axilla | Adult | Female | Aged | Sentinel Lymph Node Biopsy | Surgery
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Metronomics in the neoadjuvant and adjuvant treatment of breast cancer
by Munzone, Elisabetta and Colleoni, Marco
Cancer Letters, ISSN 0304-3835, 2017, Volume 400, pp. 259 - 266
Abstract The concept of metronomic chemotherapy (MC) has evolved from a descriptive preclinical phenomenon encompassing inhibition of angiogenesis to a... 
Hematology, Oncology and Palliative Medicine | Breast cancer | Metronomic chemotherapy | Immunomodulation | Triple negative | Neoadjuvant treatment | Adjuvant treatment | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Administration, Metronomic | Humans | Immunologic Factors - administration & dosage | Treatment Outcome | Antineoplastic Agents - administration & dosage | Triple Negative Breast Neoplasms - drug therapy | Animals | Antineoplastic Agents - adverse effects | Neoadjuvant Therapy - adverse effects | Triple Negative Breast Neoplasms - pathology | Female | Chemotherapy, Adjuvant | PEGYLATED LIPOSOMAL DOXORUBICIN | PRIMARY SYSTEMIC TREATMENT | METHOTREXATE | PHASE-II | PROGNOSTIC VALUE | CHEMOTHERAPY | INTERSTITIAL PNEUMONITIS | TUMOR-INFILTRATING LYMPHOCYTES | PREOPERATIVE TREATMENT | ONCOLOGY | ORAL CYCLOPHOSPHAMIDE | Drug therapy | Analysis | Cancer | Drugs | Clinical trials | Genomes | Metastasis | Drug development | Cancer therapies | Immunosuppressive agents | Quality of life | Studies | Angiogenesis | Chemotherapy | Lymphocytes | Antiangiogenics | Biomarkers | Breast | Bioindicators | Drug dosages | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text The added value of whole-body magnetic resonance imaging in the management of patients with advanced breast cancer
by Zugni, Fabio and Ruju, Francesca and Pricolo, Paola and Alessi, Sarah and Iorfida, Monica and Colleoni, Marco Angelo and Bellomi, Massimo and Petralia, Giuseppe
PLoS ONE, ISSN 1932-6203, 10/2018, Volume 13, Issue 10, p. e0205251
This study investigates the impact of whole-body MRI (WB-MRI) in addition to CT of chest-abdomen-pelvis (CT-CAP) and 18F-FDG PET/CT (PET/CT) on systemic... 
FDG-PET/CT | LUNG-CANCER | POSITRON-EMISSION-TOMOGRAPHY | F-18-FLUCICLOVINE PET/CT | BONE METASTASES | MRI | MULTIDISCIPLINARY SCIENCES | DIFFUSION | PROSPECTIVE CLINICAL-TRIAL | OVARIAN-CANCER | E-CADHERIN | Care and treatment | Usage | Breast cancer | Magnetic resonance imaging | Nuclear magnetic resonance--NMR | Medical imaging | Medical services | Positron emission | Pelvis | Disease control | Patients | Ovarian cancer | Computed tomography | Tomography | Mastectomy | Added value | Positron emission tomography | Cancer | NMR | Nuclear magnetic resonance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
by Bernhard, Jürg, Dr and Luo, Weixiu, MD and Ribi, Karin, PhD and Colleoni, Marco, MD and Burstein, Harold J, MD and Tondini, Carlo, MD and Pinotti, Graziella, MD and Spazzapan, Simon, MD and Ruhstaller, Thomas, MD and Puglisi, Fabio, MD and Pavesi, Lorenzo, MD and Parmar, Vani, MBBS and Regan, Meredith M, ScD and Pagani, Olivia, MD and Fleming, Gini F, MD and Francis, Prudence A, MD and Price, Karen N, BS and Coates, Alan S, MD and Gelber, Richard D, PhD and Goldhirsch, Aron, MD and Walley, Barbara A, MD
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 848 - 858
Summary Background The combined efficacy analysis of the TEXT and SOFT trials showed a significant disease-free survival benefit with exemestane plus ovarian... 
Hematology, Oncology and Palliative Medicine | IMPACT | ONCOLOGY | INDICATORS | CLINICAL-TRIALS | PREVENTION | ENDOCRINE THERAPY | SYMPTOMS | QUALITY-OF-LIFE | WORTHWHILE | POSTMENOPAUSAL WOMEN | ARIMIDEX | Follow-Up Studies | Humans | Middle Aged | Dose-Response Relationship, Drug | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Antineoplastic Agents, Hormonal - therapeutic use | Adult | Female | Ovary - drug effects | Chemotherapy, Adjuvant | Drug Administration Schedule | Risk Assessment | Administration, Oral | Early Detection of Cancer | Self Report | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - pathology | Tamoxifen - therapeutic use | Premenopause - physiology | Survival Analysis | Quality of Life | Breast Neoplasms - mortality | Tamoxifen - adverse effects | Neoplasm Staging
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
by Francis, Prudence A and Regan, Meredith M and Fleming, Gini F and Láng, István and Ciruelos, Eva and Bellet, Meritxell and Bonnefoi, Hervé R and Climent, Miguel A and Da Prada, Gian Antonio and Burstein, Harold J and Martino, Silvana and Davidson, Nancy E and Geyer, Charles E and Walley, Barbara A and Coleman, Robert and Kerbrat, Pierre and Buchholz, Stefan and Ingle, James N and Winer, Eric P and Rabaglio-Poretti, Manuela and Maibach, Rudolf and Ruepp, Barbara and Giobbie-Hurder, Anita and Price, Karen N and Colleoni, Marco and Viale, Giuseppe and Coates, Alan S and Goldhirsch, Aron and Gelber, Richard D and Int Breast Canc Study Grp and SOFT Investigators and International Breast Cancer Study Group
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 5, pp. 436 - 446
This trial did not support routine use of ovarian suppression in premenopausal breast cancer. Nevertheless, there may be some benefit from ovarian suppression... 
AMENORRHEA | MEDICINE, GENERAL & INTERNAL | THERAPY | YOUNG-WOMEN | CHEMOTHERAPY | Breast Neoplasms - surgery | Premenopause | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Mastectomy | Adult | Female | Androstadienes - therapeutic use | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use | Chemotherapy | Womens health | Invasiveness | Estrogen | Population studies | Breast cancer | Reproductive system | Tamoxifen | Drug therapy | Survival | Patients | Statistical analysis | Endocrine therapy | Radiation therapy | Cancer therapies | Survival analysis | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
by Pagani, Olivia and Regan, Meredith M and Walley, Barbara A and Fleming, Gini F and Colleoni, Marco and Láng, István and Gomez, Henry L and Tondini, Carlo and Burstein, Harold J and Perez, Edith A and Ciruelos, Eva and Stearns, Vered and Bonnefoi, Hervé R and Martino, Silvana and Geyer, Charles E and Pinotti, Graziella and Puglisi, Fabio and Crivellari, Diana and Ruhstaller, Thomas and Winer, Eric P and Rabaglio-Poretti, Manuela and Maibach, Rudolf and Ruepp, Barbara and Giobbie-Hurder, Anita and Price, Karen N and Bernhard, Jürg and Luo, Weixiu and Ribi, Karin and Viale, Giuseppe and Coates, Alan S and Gelber, Richard D and Goldhirsch, Aron and Francis, Prudence A and TEXT SOFT Investigators Int Breast and International Breast Cancer Study Group and TEXT and SOFT Investigators
The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 2, pp. 107 - 118
Aromatase inhibitors are somewhat more effective than tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer. This benefit was extended... 
TRIAL | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | TAMOXIFEN | SEQUENCE | LETROZOLE | ENDOCRINE THERAPY | FOLLOW-UP | POSTMENOPAUSAL WOMEN | AMERICAN-SOCIETY | Estradiol - blood | Breast Neoplasms - surgery | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Mastectomy | Adult | Female | Chemotherapy, Adjuvant | Aromatase Inhibitors - therapeutic use | Osteoporosis - chemically induced | Premenopause | Kaplan-Meier Estimate | Triptorelin Pamoate - adverse effects | Triptorelin Pamoate - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tamoxifen - therapeutic use | Quality of Life | Androstadienes - therapeutic use | Tamoxifen - adverse effects | Androstadienes - adverse effects | Care and treatment | Breast cancer | Research | Ovariectomy | Invasiveness | Radiation | Clinical trials | Data processing | Pituitary (anterior) | Gonadotropins | Tamoxifen | Survival | Patients | Clinical outcomes | Post-menopause | Chemotherapy | Aromatase
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights